2023
Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study
Stenger E, John T, Chellapandian D, Shah R, Gillespie S, Xiang Y, Liu K, Bhatia M, Guilcher G, Jaroscak J, Kasow K, Krajewski J, Ngwube A, Rangarajan H, Horan J, Krishnamurti L, Shenoy S, Abraham A. Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study. Blood 2023, 142: 4955. DOI: 10.1182/blood-2023-188514.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseDonor hematopoietic cell transplantationLong-term outcomesPost-HCTOrgan dysfunctionCell transplantationCell diseaseRelated donor hematopoietic cell transplantationSignificant differencesVaso-occlusive pain crisesComparable long-term outcomesLong-term outcome dataLast platelet transfusionMarkers of hemolysisCategorical variablesSymptom-free survivalSignificant organ dysfunctionHb AASickle cell traitContinuous variablesSevere clinical phenotypeSevere disease phenotypeChronic GVHDPain crisis
2018
From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea
Sinha C, Bakshi N, Ross D, Krishnamurti L. From trust to skepticism: An in-depth analysis across age groups of adults with sickle cell disease on their perspectives regarding hydroxyurea. PLOS ONE 2018, 13: e0199375. PMID: 29949647, PMCID: PMC6021071, DOI: 10.1371/journal.pone.0199375.Peer-Reviewed Original ResearchConceptsSickle cell diseaseGroup 1 participantsGroup 2 participantsCell diseaseSide effectsAdult SCD patientsPatient-related factorsPotential side effectsAdult patientsSCD patientsHU usePatients' attitudesAge 31Age groupsAge 18PatientsYoung adultsEfficacySignificant differencesAdultsEffective alternativeDiseaseRiskParticipantsQualitative interviews
2009
Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial.
Machado R, Barst R, Yovetich N, Hassell K, Goldsmith J, Woolson R, Gordeuk V, Gibbs S, Little J, Kato G, Schraufnagel D, Krishnamurti L, Girgis R, Morris C, Berman-Rosenzweig E, Badesch D, Waclawiw M, Gladwin M. Safety and Efficacy of Sildenafil Therapy for Doppler-Defined Pulmonary Hypertension in Patients with Sickle Cell Disease: Preliminary Results of the Walk-PHaSST Clinical Trial. Blood 2009, 114: 571. DOI: 10.1182/blood.v114.22.571.571.Peer-Reviewed Original ResearchSerious adverse eventsSickle cell diseaseRight heart catheterizationBrief Pain InventoryPulmonary hypertensionCell diseaseAdverse eventsArterial pressureMean pulmonary arterial pressureSix-minute walk distanceApparent safety issuesDose of sildenafilSecondary endpoint analysisWeeks of sildenafilPulmonary vascular resistancePulmonary arterial pressureTransthoracic Doppler echocardiographySystemic arterial pressurePremature study terminationSingle test doseSignificant differencesSignificant increaseSickle cell anemiaOral sildenafilSildenafil dosing
2006
Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease
Ambrusko S, Gunawardena S, Sakara A, Windsor B, Lanford L, Michelson P, Krishnamurti L. Elevation of tricuspid regurgitant jet velocity, a marker for pulmonary hypertension in children with sickle cell disease. Pediatric Blood & Cancer 2006, 47: 907-913. PMID: 16496290, DOI: 10.1002/pbc.20791.Peer-Reviewed Original ResearchConceptsElevated tricuspid regurgitant velocityTricuspid regurgitant velocitySickle cell diseaseAcute chest syndromePulmonary hypertensionCerebrovascular diseaseVasoocclusive crisisSCD patientsReticulocyte countCell diseaseType of SCDTricuspid regurgitant jet velocityLife-threatening complicationsObstructive sleep apneaPediatric SCD patientsRegurgitant jet velocityElevated reticulocyte countSignificant differencesNumber of echocardiogramsChest syndromeEchocardiographic evidenceOutpatient echocardiogramMean hemoglobinClinical characteristicsHydroxyurea therapy